ClinicalTrials.gg

Program

prabotulinumtoxin A

Also written as “ABP-450”, “PrabotulinumtoxinA-Xvfs” and “DWP450”.

Its studies are mostly in Migraine Disorders · Torticollis, led by 3 companies.

Furthest: phase 3, since Mar 28, 20219 company-led studies, 1 open or runningNext primary completion: May 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AEON Biopharma40 open or runningphase 2since Mar 28, 2021Mar 28, 2021none ahead
Daewoong Pharmaceutical31 open or runningphase 3since Mar 2, 2020Mar 2, 2020May 2028phase 3 · NCT07783763
Evolus20 open or runningphase 2since Apr 21, 2015Apr 21, 2015none ahead

Also a collaborator on its studies: ppd-development-lp and ethica-clinical-research-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 21, 2015First study: phase 2 study in Glabellar Frown LinesNew to EvolusEvolus · NCT02428608 · 570 enrolled · United States
  2. Mar 2, 2020Daewoong Pharmaceutical's first study: phase 3 study in Benign Masseteric HypertrophyNew to Daewoong PharmaceuticalDaewoong Pharmaceutical · NCT04294251 · 180 enrolled · Korea, Republic of
  3. Mar 28, 2021AEON Biopharma's first study: phase 2 study in Migraine DisordersNew to AEON BiopharmaAEON Biopharma · NCT04845178 · 797 enrolled · United States, Australia, Canada
  4. Apr 14, 20212 phase 2 studies in TorticollisAEON Biopharma · NCT04849988, NCT04871451
  5. Aug 17, 2021Phase 2 study in Migraine DisordersAEON Biopharma · NCT05016661 · 466 enrolled · United States, Australia, Canada
  6. Mar 22, 2022Phase 2 study in Glabellar Frown LinesEvolus · NCT05320393 · 154 enrolled · United States
  7. Apr 3, 2024Phase 3 study in Moderate to Severe Glabellar LinesDaewoong Pharmaceutical · NCT06354127 · 473 enrolled · China
  8. Aug 21, 2026Phase 3 study in Glabellar LinesDaewoong Pharmaceutical · NCT07783763 · 120 planned

Ahead

  1. May 2028Primary completion: phase 3 study in Glabellar LinesDaewoong Pharmaceutical · NCT07783763

TargetBeta

SNAP25 →read by rule
“Synaptosomal nerve-associated protein 25 (SNAP-25) proteolytic enzyme”ChEMBL 37, by rule

Other programs on SNAP25

ProgramCompanyFurthest phaseStudies
botulinum toxin type AAbbViephase 4286
trenibotulinumtoxinEruleAbbViephase 311

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07783763Glabellar Lines3Not yet recruitingDaewoong PharmaceuticalMay 2028120
NCT06354127Moderate to Severe Glabellar Lines · China3CompletedDaewoong PharmaceuticalNov 24, 2020473
NCT05320393Glabellar Frown Lines · United States2CompletedEvolusMay 22, 2023154
NCT05016661Migraine Disorders · United States, Australia, Canada2TerminatedAEON BiopharmaJul 31, 2024466
NCT04871451Torticollis · United States2CompletedAEON BiopharmaJul 24, 202351
NCT04849988Torticollis · United States2CompletedAEON BiopharmaJul 11, 202261
NCT04845178Migraine Disorders · United States, Australia, Canada2CompletedAEON BiopharmaJun 19, 2024797
NCT04294251Benign Masseteric Hypertrophy · Korea, Republic of3CompletedDaewoong PharmaceuticalJan 7, 2021180
NCT02428608Glabellar Frown Lines · United States2CompletedEvolusOct 2016570

How it is read

Names in the registry

  • “ABP-450”, 4 entries
  • “PrabotulinumtoxinA-Xvfs”, 2 entries
  • “DWP450”, 2 entries
  • “DWP450 20 U”, 1 entry
  • “DWP-450 (Botulinum purified neurotoxin, Type A)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.